FDA Warns of Dosing Errors in Compounded Weight Loss Drugs
Reuters
July 26, 2024
The FDA issued a warning regarding dosing errors linked to compounded versions of weight loss and diabetes drugs.
Adverse event reports, some requiring hospitalization, have been received by the FDA, associated with overdoses from incorrect self-administration by patients and dose miscalculations by health care providers.
Novo Nordisk’s weight-loss drug Wegovy is available as single-dose pre-filled pens delivering a preset dose for once-weekly administration. Similarly, the diabetes drug Ozempic from Novo Nordisk is available as multiple-dose pre-filled pens for single-patient use, also designed for once-weekly dosing.
To address this issue, the FDA advises health care providers and compounders to ensure patients receive the appropriate syringe size for their prescribed dose and to instruct patients on accurate dose measurement using the syringe.